
A.



В





FIGURE 2A










FIGURE 2 CONTINUED






% binding/uptake of Reduced Mannan-FITC by DCs





WO 2005/047507












Figure 4c











50

200

Forward Scatter


250

100 150 200


Forward Scatter

FIGURE 5 CONTINUED

Mannose-PLL-eGFP (r = 0.75)



Mannose-PEI-eGFP (r =0.75)



Degree of toxicity of various carriers




FIGURE 7

Pilot in vivo study: Proliferation assay





FIGURE 8

Pilot in vivo study: IFN-gamma ELISPOT











FIGURE 10




























Extension in vivo study: ELISPOT

ELISPOT PLOT IFN-G





 \odot

 $\widehat{\mathbf{E}}$

Area (Smm) sərA S

ဓ္တ

200

Area (mm2)

ဓ္တ

